Invesco Ltd. Increases Stake in AbbVie Inc. $ABBV

Invesco Ltd. grew its position in AbbVie Inc. (NYSE:ABBV) by 6.3% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 7,438,822 shares of the company’s stock after purchasing an additional 442,207 shares during the quarter. Invesco Ltd.’s holdings in AbbVie were worth $1,722,385,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ABBV. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie during the second quarter valued at approximately $26,000. Caitlin John LLC bought a new position in AbbVie in the 3rd quarter valued at approximately $33,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie during the 2nd quarter valued at $36,000. Delos Wealth Advisors LLC purchased a new stake in AbbVie during the 2nd quarter valued at $39,000. Finally, Redmont Wealth Advisors LLC bought a new stake in shares of AbbVie in the 3rd quarter worth $41,000. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ABBV. William Blair restated an “outperform” rating on shares of AbbVie in a research note on Monday. Berenberg Bank set a $275.00 price objective on AbbVie in a report on Tuesday, January 20th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Barclays began coverage on shares of AbbVie in a research note on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price on the stock. Finally, Evercore reduced their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Price Performance

Shares of ABBV opened at $225.36 on Friday. The firm has a market capitalization of $398.47 billion, a P/E ratio of 95.49, a PEG ratio of 0.79 and a beta of 0.34. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The business has a fifty day moving average of $224.52 and a 200 day moving average of $224.48.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie advanced a risankizumab dosing Phase 1 study, signaling continued investment in immunology R&D that supports long‑term growth expectations. AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment
• Positive Sentiment: AbbVie’s ABBV‑295 reported encouraging Phase 1 results, adding to near‑term pipeline optionality that could drive upside if later‑stage data hold. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: RBC Capital initiated coverage with an Outperform and $260 target, reflecting bullish analyst conviction around Skyrizi/Rinvoq rollout and immunology growth potential. RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
• Neutral Sentiment: Analyst fair‑value models moved only slightly and views are split — some see upside from immunology, others flag competition risk, leaving headline price targets largely unchanged. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks
• Neutral Sentiment: Market research highlights expanding opportunities in indications like bipolar depression over the coming decade, a long‑term tailwind but not an immediate catalyst. Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
• Negative Sentiment: Competitive setback: UCB’s Bimzelx outperformed AbbVie’s Skyrizi in psoriatic arthritis data, raising market‑share and pricing risk for a key immunology franchise. AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis
• Negative Sentiment: Reported insider selling drew negative attention and was cited as a near‑term headwind to sentiment and share price. AbbVie (NYSE:ABBV) Stock Price Down 1% on Insider Selling

Insider Activity at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.25% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.